BofA Securities analyst Jason Zemansky maintains $Travere Therapeutic (TVTX.US)$ with a buy rating, and adjusts the target price from $18 to $20.
According to TipRanks data, the analyst has a success rate of 50.0% and a total average return of 23.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Travere Therapeutic (TVTX.US)$'s main analysts recently are as follows:
Following a discussion with a nephrology specialist regarding the outcomes of the PARASOL Scientific Workshop, there is observed excitement about utilizing proteinuria as a primary endpoint in clinical trials. Should regulatory bodies embrace this approach, it would bode well for therapies targeting conditions such as focal segmental glomerulosclerosis (FSGS). Anticipating a potential launch in the future, the likelihood of success for such treatments is being cautiously estimated.
Following the conclusion of the PARASOL workshop, there is increased confidence in Filspari's potential approval for focal segmental glomerulosclerosis, or FSGS. This has led to a raised probability of success estimate for Filspari FSGS to 75% from the previous 60%.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
